Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) (NCT04202341)
Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies (C5ITs)
🩺 Plain-English Summary (8th-Grade Level)
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Birmingham, Alabama
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (51 Sites)
Showing the first 25 of 51 sites.
- Clinical Trial Site — Birmingham, Alabama
- Clinical Trial Site — Scottsdale, Arizona
- Clinical Trial Site — Fresno, California
- Clinical Trial Site — Orange, California
- Clinical Trial Site — Rancho Mirage, California
- Clinical Trial Site — Sylmar, California
- Clinical Trial Site — Colorado Springs, Colorado
- Clinical Trial Site — Fort Collins, Colorado
- Clinical Trial Site — New Haven, Connecticut
- Clinical Trial Site — Washington D.C., District of Columbia
- Clinical Trial Site — Clearwater, Florida
- Clincal Trial Site — Gainesville, Florida
- Clinical Trial Site — Jacksonville, Florida
- Clinical Trial Site — Tampa, Florida
- Clinical Trial Site — Augusta, Georgia
- Clinical Trial Site — Iowa City, Iowa
- Clinical Trial Site — Lexington, Kentucky
- Clinical Trial Site — Boston, Massachusetts
- Clinical Trial Site — Lansing, Michigan
- Clinical Trial Site — Columbia, Missouri
- Clinical Trial Site — New Hyde Park, New York
- Clinical Trial Site — Chapel Hill, North Carolina
- Clinical Trial Site — Charlotte, North Carolina
- Clinical Trial Site — Durham, North Carolina
- Clinical Trial Site — Dayton, Ohio
📞 Contact the Study Coordinator
Phone: (855) 752-2356
Email: clinicaltrials@alexion.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Generalized Myasthenia Gravis
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis — Scottsdale, Arizona
- A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis — Scottsdale, Arizona
- Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis — Orange, California
- Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis — Los Angeles, California
- Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis — Phoenix, Arizona
- A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. — Scottsdale, Arizona
Explore by condition: All Generalized Myasthenia Gravis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.